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ACEi/ARBs users vs. non-users (5.3% vs. 5.3%, p = 1.000). On 
univariate analysis, higher V20 (p = 0.00071), centrally 
located tumors (p = 0.00025), and higher baseline FEV1 
percentage (p = 0.03577) were associated with increased 
incidence of RP. On multivariate analysis, both higher V20 (p 
<0.0001) and centrally located tumors (p = 0.0094) were 
associated with increased incidence of RP. There was no 
identifiable relationship between age, gender, ethnicity, BMI, 
KPS, Charlson comorbidity score, smoking status or history, 
chemotherapy prior to or post SBRT, baseline DLCO, and total 
radiation dose or fractionation with the incidence of RP. 
Conclusions: The use of ACEi/ARBs at the time of lung SBRT 
did not demonstrate a significant association with the 
incidence of symptomatic RP despite previously reported 
data suggesting the opposite. Higher V20’s and centrally 
located tumors, however, were associated with increased 
incidence of RP. Given conflicting data of the protective 
effects an ACEi/ARBs may have against RP, a prospective 
evaluation is necessary.  
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Purpose/Objective: To evaluate the role of coregistered 
4DPET/CT for SBRT target delineation in patients with central 
and peripheral lung tumors. 
Materials and Methods: Analysis of internal target volume 
(ITV) delineation of central and peripheral lung lesions 
(classified according to EORTC 2211-081133) in 21 patients 
treated with SBRT. Manual delineation was performed by 4 
observers in 2 sequential contouring phases: first on 
respiratory gated 4DCT with a diagnostic 3DPET/CT available 
aside (CT-ITV) and secondly on coregistered 4DPET/CT 
(PET/CT-ITV). Comparative analysis of volumes and inter-
reader agreement was carried out for both contouring 
sessions.  
Results: Eleven cases of peripheral and 10 central lesions 
were evaluated. In peripheral lesions, CT-ITV was 6.2 cm3 
and PET/CT-ITV 8.6 cm3, with a small but significant average 
volume increase (p<0.05) resembling a mean change in 
hypothetical radius of 2 mm. For both CT-ITVs and PET/CT-
ITVs inter reader agreement was good and unchanged (0.733 
and 0.716; p=0.58). All PET/CT-ITVs stayed within the PTVs 
derived from CT-ITVs.  
In central lesions, average CT-ITVs were 42.1 cm3, PET/CT-
ITVs 44.2 cm3 with statistically not significant volume and 
hypothetical radius changes. However, inter-reader 
agreement improved significantly (0.665 and 0.750; p<0.05). 
Furthermore, 2/10 PET/CT-ITVs exceeded the PTVs derived 
from CT-ITVs by several ml. 
 
 
Conclusions: The addition of coregistered 4D-PET data to 4D-
CT based target volume delineation for SBRT of centrally 
located lung tumors increases the inter-observer agreement 
and may help in avoiding geographic misses. Hence, it may 
improve treatment accuracy and normal tissue sparing. This 
chance should be further evaluated prospectively.  
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Purpose/Objective: The purpose of this study is to analyse 
the radiotherapy (RT) treatment plans collected in the FAST-
Forward trial to ensure consistency of treatment across all 
centres and compliance with trial protocol. 
FAST-Forward is a multicentre phase III trial comparing a 1-
week course of curative whole breast RT against a standard 
3-week schedule in terms of local control and late toxicity in 
patients with early breast cancer.  
Materials and Methods: A comprehensive set of dose 
objectives for the breast PTV and organs at risk were defined 
for the trial and protocol compliance was assessed against 
these. The dose distribution should fulfil the following 
criteria: 
- PTV V95%≥90%  
- PTV V105%≤7%  
- PTV V107%≤2% 
- Dmax≤110% 
- Ipsilateral lung V30%≤17% 
- Heart V25%≤5% and V5%≤30%  
The analysis was based on a full 3D RT data review for a 
minimum of 10 randomly selected plans from each site, and 
the rest were based on evaluation of the plan assessment 
forms, completed by centres for each patient. Evaluation 
structure compliance was also checked for the reviewed 3D 
datasets. 
Results: The main trial closed after recruiting 4110 patients. 
To date, 3200 plans (78% of recruited patients) from 47 
centres have been collected. 2400 of these have been 
analysed, with full 3D RT data reviewed for 600 (25%) of 
